Targeting platelets for prevention and treatment of cardiovascular disease

Expert Opinion on Therapeutic Targets

Volumn 11, Issue 12, 2007, Pages 1523-1533

  Duhamel, Todd A ^a   Ameja, Amarjit S ^a   Dhalla, Naranjan S ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Cardiovascular diseases; Natural food products; Nutraceutical interventions; Pharmacologic interventions; Platelet aggregation and adhesion; Prevention; Therapy

Indexed keywords

ABCIXIMAB; ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; APROTININ; AURICULARIA AURICULA EXTRACT; CLOPIDOGREL; DIPYRIDAMOLE; EPTIFIBATIDE; FLAVONOID; GINGER EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; LOOP DIURETIC AGENT; LOSARTAN; LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; NUTRACEUTICAL; OMEGA 3 FATTY ACID; PENTOXIFYLLINE; RELCOVAPTAN; SARPOGRELATE; SULFINPYRAZONE; TAURINE; TICLOPIDINE; TIROFIBAN; TOLVAPTAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST;

ABSENCE OF SIDE EFFECTS; ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; AURICULARIA AURICULA; BLEEDING; CARDIOVASCULAR DISEASE; CELL FUNCTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG TARGETING; ELECTROLYTE DISTURBANCE; ENZYME INHIBITION; FOOD INDUSTRY; GINGER; GINKGO BILOBA; GINSENG; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MEDICINAL PLANT; META ANALYSIS; MONOTHERAPY; NONHUMAN; NUTRITIONAL HEALTH; PERIPHERAL VASCULAR DISEASE; PROTEIN SECRETION; REPERFUSION INJURY; REVIEW; SINGLE DRUG DOSE; SMOOTH MUSCLE FIBER; SYSTEMATIC REVIEW; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS; VASCULAR SMOOTH MUSCLE;

BLOOD PLATELETS; CARDIOVASCULAR DISEASES; HUMANS; PLATELET AGGREGATION INHIBITORS;

EID: 37349117003     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.11.12.1523     Document Type: Review

References (104)

1. TRAN H, ANAND SS: Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. JAMA (2004) 292:1867-1874.
2. SAINI HK, XU YJ, ARNEJA AS et al.: Pharmacological basis of different targets for the treatment of atherosclerosis. J. Cell Mol. Med. (2005) 9:818-839.
3. THAULOW E, ERIKSSEN J, SANDVIK L et al.: Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation (1991) 84:613-617.
4. JEREMY JY, SHUKLA N, WAN S et al.: The pathobiology of endothelin-1 in vein graft disease: are ETA receptor antagonists the solution to prevent vein graft failure? Curr. Vasc. Pharmacol. (2005) 3:315-323.
5. TANGELDER MJ, LAWSON JA, ALGRA A, EIKELBOOM BC: Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery. J. Vasc. Surg. (1999) 30:701-709.
6. DORFFLER-MELLY J, BULLER HR, KOOPMAN MM, PRINS MH: Antithrombotic agents for preventing thrombosis after infrainguinal arterial bypass surgery. Cochrane Database Syst. Rev. (2003):CD000536.
7. RODRIGUES HL: Update on the treatment with platelet antiaggregation agents. Rev. Port. Cardiol. (2001) 20:79-95.
8. BEAMISH RE, DHILLON KS, SINGAL PK, DHALLA NS: Protective effect of sulfinpyrazone against catecholamine metabolite adrenochrome-induced arrhythmias. Am. Heart J. (1981) 102:149-152.
9. MUNZEL TF, POST F: Pathogenesis and therapy of the acute coronary syndrome: differentiated advantage of glycoprotein IIb/IIIa receptor antagonists for high-risk patients. Dtsch Med. Wochenschr. (2006) 131:S215-S218.
10. KANDZARI DE: Future perspectives on antithrombin and antiplatelet therapies: novel antiplatelet and antithrombin therapies. Rev. Cardiovasc. Med. (2006) 7(Suppl. 3):S43-S52.
11. MACIA BC, RONZON FA, FERNANDEZ GE: Aspirin for the primary prevention of cardiovascular diseases in diabetic patients. A review of currently available tests. Rev. Esp. Salud Publica (2006) 80:613-620.
12. VALLES J, SANTOS MT, FUSET MP et al.: Partial inhibition of platelet thromboxane A2 synthesis by aspirin is associated with myonecrosis in patients with ST-segment elevation myocardial infarction. Am. J. Cardiol. (2007) 99:19-25.
13. FARADAY N, BECKER DM,YANEK LR et al.: Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population. Am. J. Cardiol. (2006) 98:774-779.
14. KROTZ F, HELLWIG N, SCHIELE TM et al.: Prothrombotic potential of NSAID in ischemic heart disease. Mini Rev. Med. Chem. (2006) 6:1351-1355.
15. COOKE GE, GOLDSCHMIDT-CLERMONT PJ: The safety and efficacy of aspirin and clopidogrel as a combination treatment in patients with coronary heart disease. Expert Opin. Drug Saf. (2006) 5:815-826.
16. SAINI HK, TAKEDA N, GOYAL RK et al.: Therapeutic potentials of sarpogrelate in cardiovascular disease. Cardiovasc. Drug Rev. (2004) 22:27-54.
17. SHARMA SK, ZAHRADKA P, CHAPMAN D et al.: Inhibition of serotonin-induced vascular smooth muscle cell proliferation by sarpogrelate. J. Pharmacol. Exp. Ther. (1999) 290:1475-1481.
18. ZHANG M, XU YJ, MENGI S et al.: Therapeutic potential of pentoxifylline for treatment of cardiovascular diseases. Exp. Clin. Cardiol. (2004) 9:103-111.
19. BATH PM, BATH-HEXTALL FJ: Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke. Cochrane Database Syst. Rev. (2004):CD000162.
20. LUMSDEN AB, RICE YW: Medical management of peripheral arterial disease: a therapeutic algorithm. J. Endovasc. Ther. (2006) 13:II19-II29.
21. BATCHELDER K, MAYOSI BM: Pentoxifylline for heart failure: a systematic review. S. Afr. Med. J. (2005) 95:171-175.
22. THIBONNIER M, KILANI A, RAHMAN M et al.: Effects of the nonpeptide V(1) vasopressin receptor antagonist SR49059 in hypertensive patients. Hypertension (1999) 34:1293-1300.
23. WANG J, GUO X, DHALLA NS: Modification of myosin protein and gene expression in failing hearts due to myocardial infarction by enalapril or losartan. Biochim. Biophys. Acta (2004) 1690:177-184.
24. SATO Y, FUJII S, IMAGAWA S et al.: Platelet aggregability in patients with hypertension treated with angiotensin II type 1 receptor blockers. J. Atheroscler. Thromb. (2007) 14:31-35.
25. KALINOWSKI L, MATYS T, CHABIELSKA E et al.: Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release. Hypertension (2002) 40:521-527.
26. NUNEZ A, GOMEZ J, ZALBA LR et al.: Losartan inhibits in vitro platelet activation: comparison with candesartan and valsartan. J. Renin Angiotensin Aldosterone Syst. (2000) 1:175-179.
27. KRAMER C, SUNKOMAT J, WITTE J et al.: Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ. Res. (2002) 90:770-776.
28. WELLES EG, BOUDREAUX MK, TYLER JW: Platelet, antithrombin, and fibrinolytic activities in taurine-deficient and taurine-replete cats. Am. J. Vet. Res. (1993) 54:1235-1243.
29. HAYES KC, PRONCZUK A, ADDESA AE, STEPHAN ZF: Taurine modulates platelet aggregation in cats and humans. Am. J. Clin. Nutr. (1989) 49:1211-1216.
30. NIEMI TT, MUNSTERHJELM E, POYHIA R et al.: The effect of N-acetylcysteine on blood coagulation and platelet function in patients undergoing open repair of abdominal aortic aneurysm. Blood Coagul. Fibrinolysis (2006) 17:29-34.
31. SHEN L, CUI Y: Effects of the leaf of Ginkgo biloba L. extract on blood rheology in animals. Zhongguo Zhong Yao Za Zhi (1998) 23:622.
32. KUDOLO GB, WANG W, BARRIENTOS J et al.: The ingestion of Ginkgo biloba extract (EGb 761) inhibits arachidonic acid-mediated platelet aggregation and thromboxane B2 production in healthy volunteers. J. Herb. Pharmacother. (2004) 4:13-26.
33. JIN YR, YU JY, LEE JJ et al.: Antithrombotic and antiplatelet activities of Korean red ginseng extract. Basic Clin. Pharmacol. Toxicol. (2007) 100:170-175.
34. KIMURA Y, OKUDA H, ARICHI S: Effects of various ginseng saponins on 5-hydroxytryptamine release and aggregation in human platelets. J. Pharm. Pharmacol. (1988) 40:838-843.
35. HOKAMA Y, HOKAMA JL: In vitro inhibition of platelet aggregation with low dalton compounds from aqueous dialysates of edible fungi. Res. Commun. Chem. Pathol. Pharmacol. (1981) 31:177-180.
36. THOMSON M, AL QATTAN KK, AL SAWAN SM et al.: The use of ginger ( Zingiber officinale Rosc.) as a potential anti-inflammatory and antithrombotic agent. Prostaglandins Leukot. Essent. Fatty Acids (2002) 67:475-478.
37. KUKOBA TV, SHYSH AM, MOIBENKO OO et al.: The effects of α-linolenic acid on the functioning of the isolated heart during acute myocardial ischemia/reperfusion. Fiziol Zh (2006) 52:12-20.
38. MEADOWS TA, BHATT DL: Clinical aspects of platelet inhibitors and thrombus formation. Circ. Res. (2007) 100:1261-1275.
39. VAN OEVEREN W, HARDER MP, ROOZENDAAL KJ et al.: Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg. (1990) 99:788-796.
40. MANGANO DT, TUDOR IC, DIETZEL C: The risk associated with aprotinin in cardiac surgery. N. Engl. J. Med. (2006) 354:353-365.
41. ULKER S, MCKEOWN PP, BAYRAKTUTAN U: Aprotinin impairs coronary endothelial function and down-regulates endothelial NOS in rat coronary microvascular endothelial cells. Cardiovasc. Res. (2002) 55:830-837.
42. SAMAMA CM, MAZOYER E, BRUNEVAL P et al.: Aprotinin could promote arterial thrombosis in pigs: a prospective randomized, blind study. Thromb. Haemost. (1994) 71:663-669.
43. DRAZEN JM: Research replication. N. Engl. J. Med. (2006) 355:2252-2253.
44. THIBONNIER M, KILANI A, RAHMAN M et al.: Effects of the nonpeptide V(1) vasopressin receptor antagonist SR49059 in hypertensive patients. Hypertension (1999) 34:1293-1300.
45. SHARMA SK, DEL RIZZO DF, ZAHRADKA P et al.: Sarpogrelate inhibits serotonin-induced proliferation of porcine coronary artery smooth muscle cells: implications for long-term graft patency. Ann. Thorac. Surg. (2001) 71:1856-1864.
46. TEMSAH RM, KUMAMOTO H, TAKEDA N, DHALLA NS: Sarpogrelate diminishes changes in energy stores and ultrastructure of the ischemic-reperfused rat heart. Can. J. Physiol. Pharmacol. (2001) 79:761-767.
47. BRASIL D, TEMSAH RM, KUMAR K et al.: Blockade of 5-HT(2A) receptors by sarpogrelate protects the heart against myocardial infarction in rats. J. Cardiovasc. Pharmacol. Ther. (2002) 7:53-59.
48. ZHANG M, XU YJ, SAINI HK et al.: Pentoxifylline attenuates cardiac dysfunction and reduces TNF-α level in ischemic-reperfused heart. Am. J. Physiol. Heart Circ. Physiol. (2005) 289:H832-H839.
49. 2+-overload. Biochem. Biophys. Res. Commun. (2005) 327:57-63.
50. AUKRUST P, YNDESTAD A, UELAND T et al.: Anti-inflammatory trials in chronic heart failure. Heart Fail. Monit. (2006) 5:2-9.
51. PASCARELLA L, SCHONBEIN GW, BERGAN JJ: Microcirculation and venous ulcers: a review. Ann. Vasc. Surg. (2005) 19:921-927.
52. PRASAD K, LEE P: Suppression of hypercholesterolemic atherosclerosis by pentoxifylline and its mechanism. Atherosclerosis (2007) 192:313-322.
53. XU YJ, AZIZ OA, BHUGRA P et al.: Potential role of lysophosphatidic acid in hypertension and atherosclerosis. Can. J. Cardiol. (2003) 19:1525-1536.
54. XU YJ, RATHI SS, ZHANG M et al.: Mechanism of the positive inotropic effect of lysophosphatidic acid in rat heart. J. Cardiovasc. Pharmacol. Ther. (2002) 7:109-115.
55. XU YJ, RATHI SS, CHAPMAN DC et al.: Mechanisms of lysophosphatidic acid-induced DNA synthesis in vascular smooth muscle cells. J. Cardiovasc. Pharmacol. (2003) 41:381-387.
56. BIRGBAUER E, CHUN J: New developments in the biological functions of lysophospholipids. Cell Mol. Life Sci. (2006) 63:2695-2701.
57. WEI L: Lysophospholipid signaling in cardiac myocyte hypertrophy. J. Mol. Cell Cardiol. (2004) 36:465-468.
58. OKUSA MD, YE H, HUANG L et al.: Selective blockade of lysophosphatidic acid LPA3 receptors reduces murine renal ischemia-reperfusion injury. Am. J. Physiol. Renal Physiol. (2003) 285:F565-F574.
59. TSUDA S, OKUDAIRA S, MORIYA-ITO K et al.: Cyclic phosphatidic acid is produced by autotaxin in blood. J. Biol. Chem. (2006) 281:26081-26088.
60. MURAKAMI-MUROFUSHI K, UCHIYAMA A, FUJIWARA Y et al.: Biological functions of a novel lipid mediator, cyclic phosphatidic acid. Biochim. Biophys. Acta (2002) 1582:1-7.
61. MCNEILL JR: Role of vasopressin in the control of arterial pressure. Can. J. Physiol. Pharmacol. (1983) 61:1226-1235.
62. LEMMENS-GRUBER R, KAMYAR M: Vasopressin antagonists. Cell Mol. Life Sci. (2006) 63:1766-1779.
63. STREEFKERK JO, VAN ZWIETEN PA: Vasopressin receptor antagonists: pharmacological tools and potential therapeutic agents. Auton. Autacoid Pharmacol. (2006) 26:141-148.
64. 2+] in the neonatal rat cardiomyocyte. Evidence for V1 subtype receptors. Circ. Res. (1991) 69:239-245.
65. GHEORGHIADE M: The clinical effects of vasopressin receptor antagonists in heart failure. Cleve. Clin. Med. (2007) 73:524-529.
66. ROSSI J, ORLANDI C, GHEORGHIADE M: Vasopressin antagonists in the management of heart failure. Expert Rev. Cardiovasc. Ther. (2007) 5:323-330.
67. SERRADEIL-LE GAL C, WAGNON J, GARCIA C et al.: Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. J. Clin. Invest. (1993) 92:224-231.
68. BROUARD R, LAPORTE V, SERRADEIL LG et al.: Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers. Adv. Exp. Med. Biol. (1998) 449:455-465.
69. SOLBERG OG, OMLAND T: Arginine vasopressin antagonism - new treatment option in chronic heart failure. Tidsskr Nor Laegeforen (2007) 127:179-182.
70. TRASK AJ, FERRARIO CM: Angiotensin-(1-7): pharmacology and new perspectives in cardiovascular treatments. Cardiovasc. Drug Rev. (2007) 25:162-174.
71. ISHIKAWA M, SEKIZUKA E, YAMAGUCHI N et al.: Angiotensin II type 1 receptor signaling contributes to platelet-leukocyte-endothelial cell interactions in the cerebral miscrovasculature. Am. J. Physiol. Heart Circ. Physiol. (2007) 292:H2306-H2315.
72. XIE XM, YU GL, ZHOU P: Effect of losartan and amilodipine on the platelet activation and renal function in patients with mild and moderate hypertension. Hunan Yi Ke Da Xue Xue Bao (2002) 27:130-132.
73. ENGLER MM, ENGLER MB: Omega-3 fatty adds: role in cardiovascular health and disease. J. Cardiovasc. Nurs. (2006) 21:17-24.
74. RAMAPRASAD TR, BASKARAN V, KRISHNAKANTHA TP, LOKESH BR: Modulation of antioxidant enzyme activities, platelet aggregation and serum prostaglandins in rats fed spray-dried milk containing n-3 fatty acid. Mol. Cell Biochem. (2005) 280:9-16.
75. GAMEZ R, MAZ R, ARRUZAZABALA ML et al.: Effects of concurrent therapy with policosanol and omega-3 fatty acids on lipid profile and platelet aggregation in rabbits. Drugs R&D (2005) 6:11-19.
76. FERRIER LK, CASTON LJ, LEESON S et al.: α-Linolenic acid- and docosahexaenoic acid-enriched eggs from hens fed flaxseed: influence on blood lipids and platelet phospholipid fatty acids in humans. Am. J. Clin. Nutr. (1995) 62:81-86.
77. ALLMAN MA, PENA MM, PANG D: Supplementation with flaxseed oil versus sunflowerseed oil in healthy young men consuming a low fat diet: effects on platelet composition and function. Eur. J. Clin. Nutr. (1995) 49:169-178.
78. HU FB, MANSON JE, WILLETT WC: Types of dietary fat and risk of coronary heart disease: a critical reviev. J. Am. Coll. Nutr. (2001) 20:5-19.
79. FREESE R, MUTANEN M, VALSTA LM, SALMINEN I: Comparison of the effects of two diets rich in monounsaturated fatty acids differing in their linoleic/α-linolenic acid ratio on platelet aggregation. Thromb. Haemost. (1994) 71:73-77.
80. LI D, SINCLAIR A, WILSON A et al.: Effect of dietary α-linolenic acid on thrombotic risk factors in vegetarian men. Am. Clin. Nutr. (1999) 69:872-882.
81. WANG C, HARRIS WS, CHUNG M et al.: n-3 Fatty acids from fish or fish-oil supplements, but not α-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am. J. Clin. Nutr. (2006) 84:5-17.
82. DENG YK, WEI F, LI YN: Effects of Ginkgo biloba extract (ginaton) on mRNA expression of bcl-2 and bcl-xL in myocardium of patients underwent hypothermic cardiopulmonary bypass. Zhongguo Zhong Xi Yi Jie He Za Zhi (2007) 27:256-258.
83. YEH GY, DAVIS RB, PHILLIPS RS: Use of complementary therapies in patients with cardiovascular disease. Am. J. Cardiol. (2006) 98:673-680.
84. LIU Z, LI Z, LIU X: Effect of ginsenoside Re on cardiomyocyte apoptosis and expression of Bcl-2/Bax gene after ischemia and reperfusion in rats. J. Huazhong Univ. Sci. Technolog. Med. Sci. (2002) 22:305-309.
85. XU YJ, CHEN Z, LIU J et al.: Effect of panaxadiol saponins on blood rheology. Yao Xae Tong Bao (1988) 23:284-286.
86. YU JY, JIN YR, LEE JJ et al.: Antiplatelet and antithrombotic activities of Korean red ginseng. Arch. Pharm. Res. (2006) 29:898-903.
87. YUN YP, DO JH, KO SR et al.: Effects of Korean red ginseng and its mixed prescription on the high molecular weight dextran-induced blood stasis in rats and human platelet aggregation. J. Ethnopharmacol. (2001) 77:259-264.
88. AGARWAL KC, RUSSO FX, PARKS RE Jr: Inhibition of human and rat platelet aggregation by extracts of Mo-er (Auricularia auricula). Thromb. Haemost. (1982) 48:162-165.
89. NURTJAHJAH-TJENDRAPUTRA E, AMMIT AJ, ROUFOGALIS BD et al.: Effective anti-platelet and COX-1 enzyme inhibitors from pungent constituents of ginger. Thromb. Res. (2003) 111:259-265.
90. KOO KL, AMMIT AJ, TRAN VH et al.: Gingerols and related analogues inhibit arachidonic acid-induced human platelet serotonin release and aggregation. Thromb. Res. (2001) 103:387-397.
91. NARDINI M, NATELLA F, SCACCINI C: Role of dietary polyphenols in platelet aggregation. A review of the supplementation studies. Platelets (2007) 18:224-243.
92. HOLT RR, ACTIS-GORETTA L, MOMMA TY, KEEN CL: Dietary flavanols and platelet reactivity. J. Cardiovasc. Pharmacol. (2006) 47(Suppl. 2):S187-S196.
93. MENNEN LI, SAPINHO D, DE BREE A et al.: Consumption of foods rich in flavonoids is related to a decreased cardiovascular risk in apparently healthy French women. J. Nutr. (2004) 134:923-926.
94. ARTS IC, HOLLMAN PC: Polyphenols and disease risk in epidemiologic studies. Am. J. Clin. Nutr. (2005) 81:S317-S325.
95. HEPTINSTALL S, MAY J, FOX S et al.: Cocoa flavanols and platelet and leukocyte function: recent in vitro and ex vivo studies in healthy adults. J. Cardiovasc. Pharmacol. (2006) 47(Suppl. 2):S197-S205.
96. RICE-EVANS CA, MILLER NJ, PAGANGA G: Structure-antioxidant activity relationships of flavonoids and phenotic acids. Free Radic. Biol. Med. (1996) 20:933-956.
97. MIYATA K, SHIMOKAWA H, HIGO T et al.: Sarpogrelate, a selective 5-HT2A serotonergic receptor antagonist, inhibits serotonin-induced coronary artery spasm in a porcine model. J. Cardiovasc. Pharmacol. (2000) 35:294-301.
98. MILICIC D: ACE inhibitors and angiotensin II receptor antagonists in acute coronary syndrome. Acta Med. Croatica (2004) 58:129-134.
99. GRIMM W: What is evidence-based, what is new in medical therapy of acute heart failure? Herz (2006) 31:771-779.
100. VALGIMIGLI M, AGOSTONI P, SERRUYS PW: Acute coronary syndromes: an emphasis shift from treatment to prevention; and the enduring challenge of vulnerable plaque detection in the cardiac catheterization laborator. J. Cardiovasc. Med. (2007) 8:221-229.
101. BOREK C: Garlic reduces dementia and heart-disease risk. J. Nutr. (2006) 136:S810-S812.
102. RAHMAN K, LOWE GM: Garlic and cardiovascular disease: a critical review. J. Nutr. (2006) 136:S736-S740.
103. ALLISON GL, LOWE GM, RAHMAN K: Aged garlic extract and its constituents inhibit platelet aggregation through multiple mechanisms. J. Nutr. (2006) 136:S782-S788.
104. ANDER BP, WEBER AR, RAMPERSAD PP et al.: Dietary flaxseed protects against ventricular fibrillation induced by ischemia-reperfusion in normal and hypercholesterolemic rabbits. J. Nutr. (2004) 134:3250-3256.